vs
Side-by-side financial comparison of CareDx, Inc. (CDNA) and CRISPR Therapeutics AG (CRSP). Click either name above to swap in a different company.
CareDx, Inc. is the larger business by last-quarter revenue ($117.7M vs $35.7M, roughly 3.3× CRISPR Therapeutics AG). CareDx, Inc. runs the higher net margin — 2.4% vs -104.5%, a 106.9% gap on every dollar of revenue. On growth, CareDx, Inc. posted the faster year-over-year revenue change (39.0% vs -82.3%). CareDx, Inc. produced more free cash flow last quarter ($514.0K vs $-50.3M).
CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. I...
CDNA vs CRSP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $117.7M | $35.7M |
| Net Profit | $2.8M | $-37.3M |
| Gross Margin | — | — |
| Operating Margin | — | -181.0% |
| Net Margin | 2.4% | -104.5% |
| Revenue YoY | 39.0% | -82.3% |
| Net Profit YoY | — | -141.8% |
| EPS (diluted) | $0.05 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 25 | $86.7M | — | ||
| Q1 25 | $84.7M | — | ||
| Q4 24 | $86.6M | $35.7M | ||
| Q3 24 | $82.9M | — | ||
| Q2 24 | $92.3M | — |
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $1.7M | — | ||
| Q2 25 | $-8.6M | — | ||
| Q1 25 | $-10.4M | — | ||
| Q4 24 | $87.7M | $-37.3M | ||
| Q3 24 | $-10.6M | — | ||
| Q2 24 | $-4.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | -5.6% | — | ||
| Q3 25 | -0.2% | — | ||
| Q2 25 | -12.8% | — | ||
| Q1 25 | -15.8% | — | ||
| Q4 24 | 97.5% | -181.0% | ||
| Q3 24 | -16.6% | — | ||
| Q2 24 | -7.9% | — |
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | -9.9% | — | ||
| Q1 25 | -12.2% | — | ||
| Q4 24 | 101.3% | -104.5% | ||
| Q3 24 | -12.8% | — | ||
| Q2 24 | -5.0% | — |
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $1.60 | $-0.41 | ||
| Q3 24 | $-0.20 | — | ||
| Q2 24 | $-0.09 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.9M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $1.9B |
| Total Assets | $411.1M | $2.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | — | ||
| Q3 25 | $194.2M | — | ||
| Q2 25 | $186.3M | — | ||
| Q1 25 | $230.9M | — | ||
| Q4 24 | $260.7M | $1.9B | ||
| Q3 24 | $240.9M | — | ||
| Q2 24 | $228.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | — | ||
| Q3 25 | $311.1M | — | ||
| Q2 25 | $327.4M | — | ||
| Q1 25 | $379.3M | — | ||
| Q4 24 | $378.4M | $1.9B | ||
| Q3 24 | $273.2M | — | ||
| Q2 24 | $264.7M | — |
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | — | ||
| Q3 25 | $432.3M | — | ||
| Q2 25 | $444.3M | — | ||
| Q1 25 | $489.6M | — | ||
| Q4 24 | $491.1M | $2.2B | ||
| Q3 24 | $477.0M | — | ||
| Q2 24 | $466.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.3M | $-50.0M |
| Free Cash FlowOCF − Capex | $514.0K | $-50.3M |
| FCF MarginFCF / Revenue | 0.4% | -140.9% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | 1.54× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-325.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | — | ||
| Q3 25 | $37.4M | — | ||
| Q2 25 | $9.9M | — | ||
| Q1 25 | $-26.6M | — | ||
| Q4 24 | $21.9M | $-50.0M | ||
| Q3 24 | $12.5M | — | ||
| Q2 24 | $18.9M | — |
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-50.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -140.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CDNA
| Testing services revenue | $91.4M | 78% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
CRSP
| Collaboration Revenue | $35.0M | 98% |
| Grant | $2.3M | 6% |
